Novartis Temporarily Modifies U.S. Mobile Administration Program for Sandostatin LAR During Pandemic

Due to the COVID-19 pandemic and Novartis’ ongoing commitment to support patients,  Novartis has temporarily modified the eligibility criteria related to their U.S. mobile administration program (MAP) to allow for use by patients currently receiving Sandostatin LAR therapy, regardless of insurance plan or state of residency. READ MORE


Print Friendly, PDF & Email